Virology Resource Core

病毒学资源核心

• 批准号: 10688358
• 负责人: Andrew S. Pekosz
• 金额: $ 21.11万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10688358
• 关键词: 2019-nCoV; Amino Acids; Antibody Response; Biological Assay; COVID-19; COVID-19 surveillance; Carbohydrates; Cell Culture Techniques; Cell Line; Cells; Clinical; Complex; Containment; Data; Doctor of Philosophy; Ensure; Generations; Immunity; Influenza; International; Laboratories; Lead; Mammalian Cell; Measures; Methods; Pathogenesis; Pathology; Peptides; Plaque Assay; Post-Translational Protein Processing; Production; Protein Binding Domain; Proteins; Protocols documentation; Public Health; Reagent; Recombinant Proteins; Reproducibility; Research Personnel; Research Project Grants; Resources; SARS coronavirus; SARS-CoV-2 infection; Serology; Source; Standardization; T-Lymphocyte; Testing; Time; Universities; Viral Antigens; Virion; Virus; Virus Diseases; Work; biosafety level 3 facility; experience; experimental study; improved; laboratory experience; laboratory facility; milligram; particle; protein function; reagent standardization; receptor binding; repository; respiratory virus; response; viral RNA; virology

JH-EPICS Virology Resource Core (VRC) Summary The Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS) aims to systematically analyze the innate, T cell, and antibody responses that either protect or cause pathology during SARS-CoV-2 infection. In order to accurately accomplish the Specific Aims within the three JH-EPICS Research Projects, a consistent and reliable source of virus-specific reagents and methods is required. The Virology Resource Core (VRC) is tasked with providing SARS-CoV-2-specific reagents and access to BSL3 facilities to perform experiments with virus infected cells for the three JH-EPICS Research Projects. The VRC draws on the expertise of Andrew Pekosz, PhD (Lead) and Michael Betenbaugh, PhD (Co-Lead) to generate these reagents. The VRC will produce recombinant proteins and, in particular, proteins with complex carbohydrate moieties. The VRC has the ability to use mammalian cells to express small or large quantities of purified proteins that will be used by all the JH-EPICS Research Projects to measure viral antigen specific responses. The Lead of the VRC has experience with respiratory viruses, such as influenza, SARS-CoV, and SARS-CoV-2, which will enable the VRC to rigorously and accurately grow and provide the JH-EPICS Research Projects with a consistent source of virus particles or infected cell lysates that have been inactivated and can be used in laboratories outside of BSL3-containment. The VRC will provide the expertise and access to facilities necessary to perform experiments on virus-infected cells, which will allow the JH-EPICS investigators to validate results with live virus. The centralized production of these reagents, the use of standardized protocols for virus infections, and consistent use across JH-EPICS Research Projects will improve the quality, rigor, and reproducibility of data to increase the public health significance of the JH-EPICS studies.

JH-EPICS病毒学资源核心（VRC）摘要 约翰霍普金斯SARS-CoV-2发病机制和免疫卓越中心（JH-EPICS）旨在 系统地分析先天性，T细胞和抗体反应，无论是保护或导致病理过程中， SARS-CoV-2感染。为了准确地实现《三国演义》中的具体目标， 研究项目，需要一致和可靠的病毒特异性试剂和方法来源。的 病毒学资源中心（VRC）的任务是提供SARS-CoV-2特异性试剂和BSL 3的访问 该实验室为三个JH-EPICS研究项目提供了病毒感染细胞实验设施。自愿回归委员会 利用Andrew Pekosz博士（领导）和Michael Betenbaugh博士（共同领导）的专业知识， 这些试剂。VRC将产生重组蛋白，特别是具有复合物的蛋白。 碳水化合物部分。VRC具有使用哺乳动物细胞表达少量或大量的VRC的能力。 所有JH-EPICS研究项目都将使用纯化的蛋白质来测量病毒抗原特异性 应答VRC的负责人具有处理呼吸道病毒的经验，如流感、SARS-CoV和 SARS-CoV-2将使VRC能够严格和准确地增长并提供JH-EPICS 具有一致来源的病毒颗粒或已灭活的感染细胞裂解物的研究项目 并且可以在BSL 3防护之外的实验室中使用。VRC将提供专业知识和访问 对病毒感染细胞进行实验所需的设施，这将使JH-EPICS 研究人员用活病毒验证结果。这些试剂的集中生产， 病毒感染的标准化方案，以及在JH-EPICS研究项目中的一致使用， 提高数据的质量、严谨性和可重复性，以增加JH-EPICS的公共卫生意义 问题研究